Your SlideShare is downloading. ×
Class anticoagulants 2
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Class anticoagulants 2

157
views

Published on

Published in: Health & Medicine, Technology

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
157
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
12
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

  • The blood coagulation process can be activated by one of two pathways, the tissue Factor pathway (formerly known as the extrinsic pathway) and the contact activation pathway (known as the intrinsic pathway).
    Tissue Factor binds to and activates Factor VII and the Tissue Factor/VIIa complex then activates Factor X and Factor IX to Xa and Ixa respectively. Factor X can also be converted to Xa by Ixa (in the presence of Factor VIII).
    The intrinsic pathway is activated when Factor XII comes in contact with a foreign surface. The resulting Factor XIIa then activates Factor XI, which in turn activates Factor IX. Factor Ixa then activates Factor X.
    Thus Factor Xa can be generated by activation of the tissue factor or contact activation pathways. Factor Xa then cleves prothrombin and the resulting thrombin converts fibrinogen to fibrin.
    Four of these clotting factors (Factors IX, VII, X and prothrombin) are Vitamin K dependent and therefore their activity is decreased by the Vitamin K antagonist, warfarin. The half-lives of these four Vitamin K dependent clotting factors are shown on this slide.
    Factor VII has the shortest half life of the Vitamin K dependent coagulation factors. However, for adequate anticoagulation one needs to reduce the other coagulation factors appropriately, including Factor II (prothrombin) which has a 60 hour half life. It takes several days after initiation of warfarin therapy to reduce Factor II and thus warfarin and heparin need to overlap for approximately 4–5 days when starting therapy.
  • Transcript

    • 1. Dr. RAGHU PRASADA M S MBBS,MD ASSISTANT PROFESSOR DEPT. OF PHARMACOLOGY SSIMS & RC.
    • 2. Parenteral Anticoagulants  Heparin  Low Molecular Weight Heparins- Enoxaparin Dalteparin, Tinzaparin, Ardeparin, Nadroparin, Reviparin  Synthetic Heparin Derivatives- Fondaparinux  Thrombin Inhibitors-lepirudin, Bivalirudin, Desirudin, Argatroban, Danaparoid, Drotecogin Alfa (All Parentral), Rivaroxiban, Dabigatran (Oral)
    • 3.  Coumarin derivatives: warfarin, acenocumarol, ethyl biscoumacetate and dicumarol  Indanedione group: phenindione and anisindione
    • 4. Factor Name I Fibrinogen II Prothrombin III Tissue Factor or thromboplastin IV Ca++ V Proaccelerin VII Proconvertin VIII Antihemophilic A factor IX Christmas factor or X Stuart factor XI Plasma thomboplastin antecedent XII Hageman factor XIII Fibrin stabilizing factor
    • 5. INTRINSIC PATHWAY All clotting factors are within the blood vessels  Clotting slower  Activated partial thromboplastin test (aPTT) EXTRINSIC PATHWAY Initiating factor is outside the blood vessels - tissue factor  Clotting - faster - in Seconds  Prothrombin test (PT)
    • 6.  Heparin is a non-uniform mixture of straight chain mucopolysaccharide molecules  The mean molecular weight of heparin is 15,000 D  Strongest organic acid present in body  Source- mast cells lung, liver, Int.mucosa  Actions –acts both in-vivo and invitro  Antithrombin III (ATIII) binding is necessary for its anticoagulant activity
    • 7.  Antithrombin III (ATIII) is a slow endogenous progressive inhibitor of thrombin and other clotting enzymes.  Higher doses inhibits platelet aggregation and Prolongs bleeding time.  Lipaemia clearing
    • 8.  Large, highly ionised molecule,  Bioavailability- sc -variable, IV  Does not cross –BBB or placenta  Excreted in urine  T1/2-1-4 hrsin  1000, 5000 u/ml 5ml vials  Should not be mixed with pencillins, tetracyclines.
    • 9.  Bleeding: they both lead to bleeding but the bleeding is less in LMWH  To treat bleeding: inject antidote protamine sulphate (1mg IV for each 100 units of UFH) (reversal effect)  Thrombosis: heparin ↓ ATIII ↑risk of thrombosis
    • 10.  Thrombocytopenia: Heparin-induced thrombocytopenia (HIT) is a life threatening immune reaction  HIT ↑ platelet activationplatelet aggregation thrombosis.  HIT endothelial damage  HIT may occur in the early stages of treatment (within 5 days) but it’s non-immune reaction (not life threatening)  LMWHs, though of lower risk, are contraindicated with HIT.  Osteoporosis, hyperkalemia, hypersensitivity
    • 11.  Bleeding or hemophilia  Severe hypertension  Thrombocytopenia or purpura-HIT  Intracranial hemorrhage  Recent surgery-occular, neuro, lumbar  Hypersensitivity to heparin  TB  GIT ulcer  Hepatic or renal disease, chronic alcoholics  Use of digoxin
    • 12.  M.Wt 2000-8000 Da ( avg 4500 Da )- prepared from SH by fractionation, enzymatic degradation or chem modifn  Commercial preprn : Enoxaparin, Dalteparin, Ardeparin, Tinzaparin, Reviparin, Nadroparin  Routes : SC (OD)  High anti-Xa and low anti-IIa activity↔ greater antithrombotic and lower anticoag activity  Low anti-IIa activity, hence, aPTT, TT, ACT not ideal for monitoring. Anti-Xa assay ideal  Less complicated, dose independent clearance and more predictable anticoagulant response than UFH.
    • 13.  They are as effective as standard heparin and do not require APTT monitoring  Only for prophylaxis of DVT after hip or abdominal surgery
    • 14.  Dabigatran etexilate is a new oral direct thrombin inhibitor and the prodrug of dabigatran  Dabigatran is a small molecule that reversibly inhibits both free and clot-bound thrombin by binding to exosite 1 and/or the active site of thrombin
    • 15.  Rivaroxaban is an orally available, small-molecule, active site-directed factor Xa inhibitor  There are no significant interactions between food, antacids, digoxin, aspirin, naproxen and rivaroxaban have been noted suggesting that dose adjustment of rivaroxaban would not be required when these agents are concurrently administered  Knee repalacement surgeries  Equivalent to LMWH
    • 16.  first selective factor Xa inhibitor,  55% better than enoxaparin (LMWH) at reducing risk of VTE  synthetic pentasaccharide: “represents the oligosaccharide consensus sequence of heparin”  Indirect inhibition: binds to antithrombin and increases antithrombin’s affinity for factor Xa by 300-fold  Fondaparinux is given via injection once daily  Long elimination t 1/2 (20 hrs). Renal clearance  Initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for venous thromboembolism prevention in patients undergoing surgery for hip fracture or hip/knee replacement
    • 17.  Lepirudin (DTI) derived from hirudin from leech salivary glands  Bivalirudin (DTI) approved for use during heparin- induced thrombocytopenia (HIT) & percutaneous coronary interventions  Argatroban (DTI) can be used in patients with risk of (HIT)
    • 18.  Danaparoid  Drotrecogin Alfa used in patients with sepsis; recombinant form of activated protein C that inhibits f Va and f VIIIa
    • 19.  Food and drug interactions  Genetic variation in metabolism  narrow therapeutic window  slow onset of action overlap with parenteral drugs dosage adjustments & freq. monitor with INR